Delayed gastric emptying and gastrointestinal motility effects — compounds assessed
The 2 compounds the Institute assesses in delayed gastric emptying and gastrointestinal motility effects.
§4Compounds assessed
Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.
-
GLP-1 receptor agonist (exendin-based, short- and extended-release)1 contributing trialfull monograph
Marked acute delay in gastric emptying that shows partial tachyphylaxis with continued twice-daily dosing — The clearest human demonstration of gastric-emptying tachyphylaxis in the class.
Moderate -
Growth-hormone secretagogue, selective ghrelin receptor agonist (pentapeptide)1 contributing trialfull monograph
A phase 2 programme in post-operative ileus did not meet its primary endpoint and development was discontinued — The Institute regards the existence of a discontinued phase 2 programme with a negative primary endpoint as the most clinically informative fact…
Moderate
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine 2017;377(13):1228–1239. doi:10.1056/NEJMoa1612917 · PMID 28910237
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.